(Q39177983)

9 September 2017

Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions (English)

1 reference

9 September 2017

1

0 references

Ilkka Kalliala

2

0 references

Eeva Auvinen

5

0 references

author name string

Tadeusz Dyba

3

1 reference

PubMed ID

27858961

9 September 2017

Pekka Nieminen

4

1 reference

9 September 2017

13 October 2016

1 reference

Acta Obstetricia et Gynecologica Scandinavica

9 September 2017

1 reference

9 September 2017

96

1 reference

9 September 2017

1

1 reference

9 September 2017

61-68

1 reference

Papillomaviruses and cancer: from basic studies to clinical application

9 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Note on the sampling error of the difference between correlated proportions or percentages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Natural history of cervicovaginal papillomavirus infection in young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Regression of low-grade squamous intra-epithelial lesions in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

HPV-mediated cervical carcinogenesis: concepts and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Evaluating HPV-negative CIN2+ in the ATHENA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Are 20 human papillomavirus types causing cervical cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FAOGS.13041

21 January 2018

Identifiers

DOI

10.1111/AOGS.13041

1 reference

9 September 2017

1 reference

PubMed ID

27858961